Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-03-07
1998-04-28
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 34, 514242, 514274, 514283, 514322, 536 245, A61K 3144, A61K 3153, A61K 3170, A61K 31445, A61K 31505, A61K 4800, C07H 2104
Patent
active
057444609
ABSTRACT:
The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein. In particular, the invention relates to products or combinations comprising antisense oligonucleotides or oligonucleotide derivatives targeted to nucleic acids encoding human PKC and other (preferably standard) chemotherapeutics, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined use of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, that can be treated by inhibition of PKC activity, that is, where the antisense oligonucleotides or oligonucleotide derivatives are targeted to nucleic acids encoding the regulatory protein PKC or active mutated derivatives thereof.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5525490 (1996-06-01), Erickson et al.
patent: 5539094 (1996-07-01), Reed et al.
patent: 5550019 (1996-08-01), Reed
patent: 5585479 (1996-12-01), Hoke et al.
G. K. Schwartz, et al., J. Natl. Cancer Inst., vol. 87, No. 18, 1995, pp. 1394-1399.
Uhlmann E, et al. "Antisense oligonucleotides: A new therapeutic principle." Chem. Rev. 90: 543-584, 1990.
Skorski T, et al. "Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligonucleotides combined with mafosfamide." J. Clin. Invest. 92: 194-202, 1993.
Malgorzata N-S. "Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment." Folia Histochemica et Cytobiologica 32: 35-40, 1994.
Monia BP. "Evaluation of 2' modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression." JBC 268: 14514-14522, 1993.
Nishizuka Y. "The molecular heterogeneity of protein kinase C and its implications for cellular regulation." Nature 334: 661-665, 1988.
Orkin SH. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.", 1995.
Szczylik et al "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides" Science vol. 253 (1991) pp. 562-565.
Nieborowska-Skorska| "Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment ?." Folia Histochemica et Cytobiologica, vol. 32, No. 1, 1994 pp. 35-40.
Taroszewski et al "Concerning Antisense Inhibition of the Multiple Drug Resistance Gene" Cancer Communications, vol. 2, No. 8 1990 (pp. 287-294).
Isis Pharmaceuticals Press Release dated Jan. 23, 1996, "Isis Pharmaceuticals Initiates Clinical trials with Novel Antisense Cancer Compound Targeted to PKC-a Inhibition".
Calabretta "Inhibition of Protooncogene Expression by Antisense Oligodeoxynucleotides: Biological and Therapeutic Implications" Cancer Research 54, 4505-4510 Sep. 1991.
Skorski et al "Highly Efficient Elimination of Philadelphia Leukemic Cells by Exposure to bcr/abl Antisense Oligodeoxynucleotides Combined with Mafosfamide" J Clinical Invest vol. 92, (1993) 194-202.
Corrias "An Oligomer Complimontary to the 5' End Region of MDRL Gene Decreases Resistance to Doxorubicin of Human Adenocarcinoma-Resistance Cells" Anticancer Research 12, 1431-1438 (1992).
Chemical Abstract, vol. 37, No. 2807, 511, 1996.
Guleria et al, Nature Medicine 2 (3), 334 (1996).
Mizutani et al, Cancer 74 (9), 2546 (1994).
Milligan et al, J. Med. Chem 36 (14), 1923 (1993).
Clark et al, Cancer Supplement 78 (3), 688 (1996).
Chemical Abstract, vol. 37, No. 240.5, 352, 1996.
Ma et al, Fundam Clin. Pharmacol. 10, 97-115 (1996).
Citti et al, Carcinogenesis 17 (1), 25-29 (1996).
Chemical Abstract, vol. 86, No. 2955, 1, 742a, (1995).
Chemical Abstract, vol. 36, No. 2571, 431 (1995).
Chemical Abstract, vol. 36, No. 2032, 341, (1996).
Chemical Abstract, vol. 36, No. 1704, 287, (1996).
Steele et al, Cancer Research 53, 2330 (1993).
Chemical Abstract, vol. 153, No. 166, 270A, (1995).
Chemical Abstract, vol. 84, No. 2043, 1,514a (1994).
Chemical Abstract, vol. 35, No. 1543, 258, (1994).
Chemical Abstract, vol. 84, No. 552, (1994).
Tortora et al, Biochem. Biophys. Res. Commun. 177 (3), 1133 (1991).
Chemical Abstract, vol. 32, No. 2570, (1991).
Chemical Abstract, vol. 31, No. 221, (1990).
Alama et al., Pharm Res. 22, Suppl. 2,2 (1990).
Dean et al, J. Biol. Chem. 269 (23), 16416-24(1994).
Maier, et al, Experimental Cell Research 205, 52-58 (1993).
The Genesis Report/Rx, Jun. 1993, p. 15.
Ahmad et al, Mol. Pharmacology 43, 858 (1993).
Chemical Abstract, vol. 33, No. 550, 92, (1992).
Chemical Abstract, vol. 57, (2), 1005-B (1996).
Cho-Chung et al, Pharm. Ther. 60, 265-88 (1993).
Roninson: Cancer Biotechnology Weekly Nov. 6, 1995.
Blagosklonny et al, Cancer Researcher Weekly Sep. 26, 1994.
Cho-Chung: Crisp data Base NIH, Publication year 1994 (entered into database Jul. 1995).
Chemical Abstract, vol. 95, 206843, (1994).
Blagosklonny et al, Anti-Cancer Drugs 5, 437-442 (1994).
Baltuch et al, J. Neuro-Oncology 24, 241-50 (1995).
Proc. Amer. Assoc. Cancer Res. vol. 35, p. 617, No. 3680 (1994).
Altmann Karl-Heinz
Bennett Clarence Frank
Dean Nicholas M.
Fabbro Doriano
Geiger Thomas
Nelson Amy J.
Novartis Corporation
Nowak Henry P.
Robinson Douglas W.
LandOfFree
Combination for treatment of proliferative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination for treatment of proliferative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination for treatment of proliferative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532077